PIPELINE Collaborations and Partnerships
Delivering on the RNA Revolution
We are advancing and expanding our innovative AOC pipeline to offer treatment options for patients and their families across a wide range of therapeutic areas. We have three AOC programs for three distinct rare diseases in clinical development from our muscle disease franchise: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne Muscular Dystrophy (DMD). Our pipeline also includes advancing AOCs to address additional DMD, rare neuromuscular, and rare precision cardiology programs. We continue to broaden our reach of AOCs in other indications including cardiology and immunology through partnerships.
At Avidity, our goal is to discover, develop and commercialize novel AOC™ therapeutics that overcome current barriers to the delivery of oligonucleotides and unlock their potential to treat a wide range of serious diseases currently lacking adequate treatment options.
We continue to broaden the reach of AOCs with our advancing and expanding pipeline as we transform to become a global commercial organization. In addition to our own internal research programs, we continue to explore the full potential of our AOC platform through collaborations and partnerships, including programs in immunology, cardiology and other select indications outside of muscle.
PRECISION CARDIOLOGY
In November 2023, Avidity announced a global licensing and research collaboration with Bristol Myers Squibb focused on the discovery, development and commercialization of multiple cardiovascular targets. This strategic collaboration broadens the reach of AOCs through the expansion of the existing relationship with Bristol Myers Squibb. In addition, we continue to advance our own internal research and development programs in rare cardiac indications.
IMMUNOLOGY
In April 2019, Avidity entered into a research collaboration and license agreement with Eli Lilly and Company for the discovery, development and commercialization of AOCs directed against certain targets in immunology and other select indications on a worldwide basis.